Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Anemia
Continuous erythropoietin receptor activator for anemia study results reported
July 7th, 2005
New data from a year-long study have shown that CERA, the first continuous erythropoietin receptor activator from Roche, provided sustained and stable control of hemoglobin levels with dosing intervals up to 4 weeks in dialysis patients who suffer from anemia. A combined analysis of this study and another, found that hemoglobin levels were maintained within the target range recommended by international treatment guidelines and were achieved irrespective of patients' gender, race, age or diabetic status. These data were presented during the European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) congress in Istanbul. ...
Source: Women's Health Weekly (2005-07-07)
|
